WT1 and acute myeloid leukemia: Maslak et al. reported a median disease-free survival of 16.9 months and median OS estimated to be ≥ 67.6 months in a cohort of 22 AML patients in CR after induction therapy receiving multivalent WT1 peptide vaccine [29].